(Q40865388)

24 September 2017

1 reference

title

Opportunistic/nosocomial infections. Treatment and developmental therapeutics. Toxoplasmosis (English)

1 reference

hospital-acquired infection

24 September 2017

0 references

1 reference

St Georgiev V

1

1 reference

24 September 2017

publication date

1 September 1993

1 reference

Medicinal Research Reviews

24 September 2017

published in

1 reference

24 September 2017

volume

13

1 reference

24 September 2017

issue

5

1 reference

24 September 2017

page(s)

529-568

1 reference

Toxoplasmosis mimicking a brain abscess in an adult with treated scleroderma

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

AIDS commentary. Toxoplasmic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Toxoplasmosis in the compromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Toxoplasmosis in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vitro assessment of antimicrobial agents against Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

[The trimethoprim-sulfamethoxazole association in experimental toxoplasmosis in mice].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole) and spiramycin in pregnant mice infected with Toxoplasma gondii (Beverley strain).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Adult toxoplasmosis presenting as polymyositis and cerebellar ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Effect of clindamycin on acute and chronic toxoplasmosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Clindamycin in a murine model of toxoplasmic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Effect of roxithromycin on acute toxoplasmosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

In vivo activity of piritrexim [corrected] against Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Incorporation of Precursors into Toxoplasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.2610130503

21 January 2018

Identifiers

DOI

10.1002/MED.2610130503

1 reference

24 September 2017

1 reference